Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs

Galectin Therapeutics

31/03/2026 13:09

Overview

U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end

Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027

Outlook

Company expects to fund planned operations and R&D activities through April 2027 with current cash and credit

Result Drivers

R&D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trial

Company press release: ID:nGNXXBl8B

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$0.48


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)